TrueBinding

Healthcare Business Today featured TrueBinding's potentially groundbreaking investigational treatment, TB006, while highlighting the growing significance of early and regular Alzheimer's screenings as the elderly population expands.

The article explores the significance of this development, accentuating TB006's
potential capacity to reverse Alzheimer's disease, setting it apart in biotechnology
research.

In clinical trials, patients experienced improved cognitive function in Alzheimer's, unlike treatments that decelerate disease progression.

Gain deeper insights into TrueBinding's TB006, by reading the full article:

You Can’t Reverse Aging, But TrueBinding May Be Able To Reverse Alzheimer’s - Healthcare Business Today Right now, human clinical trials and an Expanded Access Program (EAP) are underway for TB006, an investigational medication for the treatment of Alzheimer’s

Alzheimer's disease affects millions of lives, and it's important to recognize that almost two-thirds of Americans living with Alzheimer's are women.

This gender disparity is a sobering fact that highlights the need for greater awareness and research into Alzheimer's, particularly its impact on women.

By understanding the unique challenges women face in the battle against Alzheimer's, we can take meaningful steps toward improved care, prevention and support.

Follow us to learn more about our mission to combat neurodegenerative diseases.